Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy ProgramGlobeNewsWire • 12/06/23
Voyager Therapeutics' Strategic Partnerships And TRACER Technology - Speculative BuySeeking Alpha • 12/04/23
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating ResultsGlobeNewsWire • 11/06/23
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and WebcastGlobeNewsWire • 10/30/23
Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business OfficerGlobeNewsWire • 08/07/23
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating ResultsGlobeNewsWire • 08/03/23
Voyager Therapeutics Announces Second Quarter 2023 Conference Call and WebcastGlobeNewsWire • 07/27/23
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal OfficerGlobeNewsWire • 07/10/23
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion DiseaseBusiness Wire • 06/29/23
Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?Zacks Investment Research • 06/21/23
Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual MeetingGlobeNewsWire • 05/18/23
Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass EstimatesZacks Investment Research • 05/09/23
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating ResultsGlobeNewsWire • 05/09/23
Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of DirectorsGlobeNewsWire • 05/09/23
Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?Zacks Investment Research • 05/04/23
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual MeetingGlobeNewsWire • 05/02/23